COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval

Expert Review of Anti-Infective Therapy · Published 2026-01-02 · DOI 10.1080/14787210.2026.2623136

Authors being retrieved — see the publisher record. https://doi.org/10.1080/14787210.2026.2623136

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year: 2026

Related articles

Convalescent plasma for persistent symptomatic COVID-19 infection in immune-suppressed patients – a case series · Infectious Medicine · 2026 · Cites or is cited by this article
Post-tuberculosis lung disease and pulmonary aspergillosis management: challenges and considerations · Expert Review of Anti-Infective Therapy · 2026 · Same journal
Non-prescription antibiotic dispensing and counseling practices in Iraqi community pharmacies: implications for antimicrobial stewardship and resistance containment · Expert Review of Anti-Infective Therapy · 2026 · Same journal
Current perspectives of bacteriophage therapy for multidrug-resistant wound infections · Expert Review of Anti-Infective Therapy · 2026 · Same journal
How ready are we to use artificial intelligence in our fight against antimicrobial resistance? An ESGAID and EAAS perspective · Expert Review of Anti-Infective Therapy · 2026 · Same journal
Diagnosis and treatment of congenital toxoplasmosis: an updated overview · Expert Review of Anti-Infective Therapy · 2026 · Same journal
Self-medication with antibiotics and knowledge and attitudes toward rational antibiotic use among women of reproductive age · Expert Review of Anti-Infective Therapy · 2026 · Same journal
Tigecycline use in children with multidrug-resistant infections: a single-center experience · Expert Review of Anti-Infective Therapy · 2026 · Same journal
Hepatitis B in pregnancy and breastfeeding: current approaches to prophylaxis and treatment · Expert Review of Anti-Infective Therapy · 2026 · Same journal
An evaluation of sipavibart for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals · Expert Review of Anti-Infective Therapy · 2026 · Same journal